CL2015000711A1 - Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer. - Google Patents

Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.

Info

Publication number: CL2015000711A1
Authority: CL; Chile
Prior art keywords: benzodiazepinone; fluoroalkyl; bis; pharmaceutical composition; cancer treatment
Prior art date: 2012-09-21

Application number

CL2015000711A

Other languages

English (en)

Inventor

Ashvinikumar V Gavai

George V Delucca

Daniel O'malley

Patrice Gill

Brian E Fink

Yufen Zhao

Francis Y Lee

Claude A Quesnelle

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-21

Filing date

2015-03-20

Publication date

2015-09-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49263506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000711(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-03-20 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2015-09-04 Publication of CL2015000711A1 publication Critical patent/CL2015000711A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

CL2015000711A 2012-09-21 2015-03-20 Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer. CL2015000711A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261703912P	2012-09-21	2012-09-21

Publications (1)

Publication Number	Publication Date
CL2015000711A1 true CL2015000711A1 (es)	2015-09-04

Family

ID=49263506

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2015000711A CL2015000711A1 (es)	2012-09-21	2015-03-20	Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.

Country Status (35)

Country	Link
US (2)	US8999918B2 (es)
EP (1)	EP2897945B1 (es)
JP (1)	JP6165255B2 (es)
KR (1)	KR102155588B1 (es)
CN (1)	CN104703976B (es)
AR (1)	AR093767A1 (es)
AU (1)	AU2013317923B2 (es)
BR (1)	BR112015005817B1 (es)
CA (1)	CA2885574C (es)
CL (1)	CL2015000711A1 (es)
CO (1)	CO7310522A2 (es)
CY (1)	CY1118739T1 (es)
DK (1)	DK2897945T3 (es)
EA (1)	EA027281B1 (es)
ES (1)	ES2617591T3 (es)
HR (1)	HRP20170352T8 (es)
HU (1)	HUE032038T2 (es)
IL (1)	IL237782A (es)
LT (1)	LT2897945T (es)
MA (1)	MA37929B1 (es)
MX (1)	MX367474B (es)
MY (1)	MY185233A (es)
NZ (1)	NZ707171A (es)
PE (1)	PE20150622A1 (es)
PH (1)	PH12015500414A1 (es)
PL (1)	PL2897945T3 (es)
PT (1)	PT2897945T (es)
RS (1)	RS55779B1 (es)
SG (1)	SG11201501573UA (es)
SI (1)	SI2897945T1 (es)
SM (1)	SMT201700153T1 (es)
TN (1)	TN2015000102A1 (es)
TW (1)	TWI614238B (es)
UY (1)	UY35041A (es)
WO (1)	WO2014047372A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2897938B1 (en)	2012-09-21	2017-03-15	Bristol-Myers Squibb Company	Fluoroalkyl dibenzodiazepinone compounds
JP2015529253A (ja)	2012-09-21	2015-10-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｎｏｔｃｈ阻害剤としてのフルオロアルキルおよびフルオロシクロアルキル１，４−ベンゾジアゼピノン化合物
JP2015529252A (ja)	2012-09-21	2015-10-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	フルオロアルキル−１，４−ベンゾジアゼピノン化合物
EP2897960B1 (en)	2012-09-21	2016-08-03	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds as notch inhibitors
WO2014047369A1 (en)	2012-09-21	2014-03-27	Bristol-Myers Squibb Company	Substituted 1,5-benzodiazepinone compounds
JP2015534554A (ja)	2012-09-21	2015-12-03	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
JP2015531792A (ja)	2012-09-21	2015-11-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	１，４−ベンゾジアゼピノン化合物のプロドラッグ
WO2014047393A1 (en) *	2012-09-21	2014-03-27	Bristol-Myers Squibb Company	N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
JP2016515625A (ja)	2013-04-04	2016-05-30	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	増殖性疾患を治療するための併用療法
BR112017015693A2 (pt)	2015-02-03	2018-03-20	Pfizer	ciclopropabenzofuranil piridopirazinadionas
WO2019215585A1 (en) *	2018-05-06	2019-11-14	Ayala Pharmaceuticals Inc.	Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
EP3790552A4 (en) *	2018-05-06	2022-06-15	Ayala Pharmaceuticals Inc.	COMBINATION COMPOSITIONS WITH BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THERE
EP3793564A4 (en) *	2018-05-15	2022-03-30	Ayala Pharmaceuticals Inc.	COMPOSITIONS CONTAINING BISFLUOROALKYL-L,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF ADENOCARCINOMA
MX2020012281A (es) *	2018-05-15	2021-01-29	Bristol Myers Squibb Co	Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2020012561A (es) *	2018-05-24	2021-01-29	Ayala Pharmaceuticals Inc	Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas.
WO2020072602A1 (en)	2018-10-02	2020-04-09	Frequency Therapeutics, Inc.	Pharmaceutical compositions comprising otic therapeutic agents and related methods
CA3136424A1 (en)	2019-04-08	2020-10-15	Frequency Therapeutics, Inc.	Combination of chir99021 and valproic acid for treating hearing loss
MX2022010079A (es) *	2020-02-16	2022-09-02	Ayala Pharmaceuticals Inc	Metodos para preparar derivados quirales de benzodiazepinona.
EP4208162A4 (en) *	2020-09-03	2024-08-21	Bristol-Myers Squibb Company	Polymorphs of bis(fluoroalkyl)-1,4-benzodiazepinone compounds and uses thereof
CN112142629B (zh) *	2020-10-10	2021-09-14	西北工业大学	3-氨基磺酰基丙氨酸的制备方法
EP4008324A1 (en)	2020-12-07	2022-06-08	Cellestia Biotech AG	Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
EP4255409A1 (en)	2020-12-07	2023-10-11	Cellestia Biotech AG	Pharmaceutical combinations for treating cancer
EP4346816A2 (en)	2021-06-02	2024-04-10	Cellestia Biotech AG	Compounds for use in a method for treating an autoimmune and inflammatory disease
WO2023079132A1 (en)	2021-11-08	2023-05-11	Cellestia Biotech Ag	Pharmaceutical combinations for treating cancer
EP4223292A1 (en)	2022-02-07	2023-08-09	Cellestia Biotech AG	Pharmaceutical combinations for treating cancer
WO2024036097A1 (en)	2022-08-12	2024-02-15	Nuvalent, Inc.	Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2024145306A1 (en) *	2022-12-28	2024-07-04	Ayala Pharmaceuticals Inc.	Intermediate salt for the preparation of bis(fluoroalkyl) benzodiazepinone compounds
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025072117A1 (en)	2023-09-25	2025-04-03	Nuvalent, Inc.	Heteroaromatic macrocyclic ether compounds and isotopologues thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5324726A (en)	1989-12-18	1994-06-28	Merck & Co., Inc.	Benzodiazepine analogs
US5852010A (en)	1996-04-03	1998-12-22	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
CA2250203A1 (en)	1996-04-03	1997-10-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6635632B1 (en)	1996-12-23	2003-10-21	Athena Neurosciences, Inc.	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
NZ509241A (en)	1998-08-07	2003-08-29	Du Pont Pharm Co	Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en)	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
US6737038B1 (en)	1998-11-12	2004-05-18	Bristol-Myers Squibb Company	Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1129355B1 (en)	1998-11-12	2005-07-20	Bristol-Myers Squibb Pharma Company	Use of radioligands to screen inhibitors of amyloid-beta peptide production
WO2000038618A2 (en)	1998-12-24	2000-07-06	Du Pont Pharmaceuticals Company	SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
EP2062583B1 (en)	1999-04-30	2012-12-26	The Regents of the University of Michigan	Therapeutic applications of pro-apoptotic benzodiazepines
US6960576B2 (en)	1999-09-13	2005-11-01	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en)	1999-09-13	2003-01-07	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
WO2001027091A1 (en)	1999-10-08	2001-04-19	Du Pont Pharmaceuticals Company	AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
WO2001053255A1 (en)	2000-01-24	2001-07-26	Merck Sharp & Dohme Limited	Gamma-secretase inhibitors
EP1261610A2 (en) *	2000-02-17	2002-12-04	Bristol-Myers Squibb Pharma Company	Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
US6495540B2 (en)	2000-03-28	2002-12-17	Bristol - Myers Squibb Pharma Company	Lactams as inhibitors of A-β protein production
AU2001251147A1 (en)	2000-03-31	2001-10-15	Dupont Pharmaceuticals Company	Succinoylamino heterocycles as inhibitors of abeta protein production
BR0110051A (pt)	2000-04-03	2004-12-07	Bristol Myers Squibb Pharma Co	Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
IL151576A0 (en)	2000-04-03	2003-04-10	Bristol Myers Squibb Pharma Co	Cyclic lactams as inhibitors of a-beta protein production
GB0008710D0 (en)	2000-04-07	2000-05-31	Merck Sharp & Dohme	Therapeutic compounds
WO2001077086A1 (en)	2000-04-11	2001-10-18	Dupont Pharmaceuticals Company	SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
WO2001087354A2 (en)	2000-05-17	2001-11-22	Bristol-Myers Squibb Pharma Company	Use of small molecule radioligands for diagnostic imaging
GB0012671D0 (en)	2000-05-24	2000-07-19	Merck Sharp & Dohme	Therapeutic agents
IL147629A0 (en) *	2000-06-01	2002-08-14	Bristol Myers Squibb Pharma Co	LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US7001901B2 (en)	2002-08-27	2006-02-21	Bristol-Myers Squibb Company	Tetrazolylpropionamides as inhibitors of Aβ protein production
EA012387B1 (ru) *	2002-09-20	2009-10-30	Эрроу Терапьютикс Лимитед	Производные бензодиазепина, содержащие их продукт и фармацевтическая композиция и их применение
EP1592684B1 (en)	2003-02-04	2008-07-30	F. Hoffmann-La Roche Ag	Malonamide derivatives as gamma-secretase inhibitors
GB0312365D0 (en)	2003-05-30	2003-07-02	Univ Aston	Novel 3-substituted-1, 4-benzodiazepines
BRPI0413533A (pt)	2003-09-09	2006-10-10	Hoffmann La Roche	derivados de malonamida que bloqueiam a atividade de gama-secretase
EP1795198A1 (en)	2005-12-09	2007-06-13	Hubrecht Laboratorium	Treatment of Barret's esophagus
BRPI0815135A2 (pt)	2007-08-14	2015-02-03	Lilly Co Eli	Derivados de azepina como inibidores de gama secretase.
KR20100101624A (ko)	2008-01-11	2010-09-17	에프. 호프만-라 로슈 아게	암 치료를 위한 감마-세크레타제 저해제의 용도
TWI530489B (zh) *	2011-03-22	2016-04-21	必治妥美雅史谷比公司	雙（氟烷基）－１，４－苯二氮呯酮化合物
WO2014047393A1 (en) *	2012-09-21	2014-03-27	Bristol-Myers Squibb Company	N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors

2013
- 2013-09-18 TW TW102133985A patent/TWI614238B/zh active
- 2013-09-20 MX MX2015003033A patent/MX367474B/es active IP Right Grant
- 2013-09-20 SM SM20170153T patent/SMT201700153T1/it unknown
- 2013-09-20 HU HUE13770806A patent/HUE032038T2/en unknown
- 2013-09-20 LT LTEP13770806.1T patent/LT2897945T/lt unknown
- 2013-09-20 CN CN201380048504.4A patent/CN104703976B/zh active Active
- 2013-09-20 BR BR112015005817-5A patent/BR112015005817B1/pt active IP Right Grant
- 2013-09-20 WO PCT/US2013/060790 patent/WO2014047372A1/en active Application Filing
- 2013-09-20 US US14/032,333 patent/US8999918B2/en active Active
- 2013-09-20 PL PL13770806T patent/PL2897945T3/pl unknown
- 2013-09-20 CA CA2885574A patent/CA2885574C/en active Active
- 2013-09-20 NZ NZ707171A patent/NZ707171A/en unknown
- 2013-09-20 EA EA201590581A patent/EA027281B1/ru not_active IP Right Cessation
- 2013-09-20 DK DK13770806.1T patent/DK2897945T3/en active
- 2013-09-20 PT PT137708061T patent/PT2897945T/pt unknown
- 2013-09-20 KR KR1020157006776A patent/KR102155588B1/ko active Active
- 2013-09-20 MY MYPI2015700879A patent/MY185233A/en unknown
- 2013-09-20 EP EP13770806.1A patent/EP2897945B1/en active Active
- 2013-09-20 JP JP2015533198A patent/JP6165255B2/ja active Active
- 2013-09-20 MA MA37929A patent/MA37929B1/fr unknown
- 2013-09-20 RS RS20170259A patent/RS55779B1/sr unknown
- 2013-09-20 SG SG11201501573UA patent/SG11201501573UA/en unknown
- 2013-09-20 ES ES13770806.1T patent/ES2617591T3/es active Active
- 2013-09-20 AR ARP130103390A patent/AR093767A1/es not_active Application Discontinuation
- 2013-09-20 PE PE2015000392A patent/PE20150622A1/es active IP Right Grant
- 2013-09-20 UY UY0001035041A patent/UY35041A/es active IP Right Grant
- 2013-09-20 AU AU2013317923A patent/AU2013317923B2/en active Active
- 2013-09-20 SI SI201330507A patent/SI2897945T1/sl unknown
2015
- 2015-02-20 US US14/627,573 patent/US9273014B2/en active Active
- 2015-02-26 PH PH12015500414A patent/PH12015500414A1/en unknown
- 2015-03-12 CO CO15057524A patent/CO7310522A2/es unknown
- 2015-03-16 IL IL237782A patent/IL237782A/en active IP Right Grant
- 2015-03-17 TN TNP2015000102A patent/TN2015000102A1/fr unknown
- 2015-03-20 CL CL2015000711A patent/CL2015000711A1/es unknown
2017
- 2017-03-03 HR HRP20170352TT patent/HRP20170352T8/hr unknown
- 2017-03-16 CY CY20171100338T patent/CY1118739T1/el unknown

Also Published As

Publication number	Publication date
TW201418230A (zh)	2014-05-16
PH12015500414B1 (en)	2015-04-20
DK2897945T3 (en)	2017-03-27
UY35041A (es)	2014-03-31
PH12015500414A1 (en)	2015-04-20
SI2897945T1 (sl)	2017-03-31
TN2015000102A1 (en)	2016-06-29
EA201590581A1 (ru)	2015-07-30
NZ707171A (en)	2018-01-26
HRP20170352T1 (hr)	2017-05-05
MX367474B (es)	2019-08-23
AR093767A1 (es)	2015-06-24
EP2897945B1 (en)	2016-12-21
CN104703976A (zh)	2015-06-10
PT2897945T (pt)	2017-03-07
US20150166489A1 (en)	2015-06-18
US8999918B2 (en)	2015-04-07
TWI614238B (zh)	2018-02-11
JP6165255B2 (ja)	2017-07-19
ES2617591T3 (es)	2017-06-19
PE20150622A1 (es)	2015-05-11
US20140087992A1 (en)	2014-03-27
WO2014047372A1 (en)	2014-03-27
RS55779B1 (sr)	2017-07-31
LT2897945T (lt)	2017-03-27
IL237782A (en)	2017-03-30
CO7310522A2 (es)	2015-06-30
AU2013317923B2 (en)	2017-06-29
EP2897945A1 (en)	2015-07-29
MA37929B1 (fr)	2018-09-28
KR102155588B1 (ko)	2020-09-14
JP2015530411A (ja)	2015-10-15
AU2013317923A1 (en)	2015-05-07
CA2885574C (en)	2021-06-08
PL2897945T3 (pl)	2017-06-30
MY185233A (en)	2021-04-30
SG11201501573UA (en)	2015-05-28
CY1118739T1 (el)	2017-07-12
HUE032038T2 (en)	2017-09-28
HRP20170352T8 (hr)	2017-05-19
BR112015005817B1 (pt)	2022-10-04
CA2885574A1 (en)	2014-03-27
MA37929A1 (fr)	2018-06-29
US9273014B2 (en)	2016-03-01
EA027281B1 (ru)	2017-07-31
SMT201700153T1 (it)	2017-05-08
KR20150056780A (ko)	2015-05-27
MX2015003033A (es)	2015-06-10
CN104703976B (zh)	2017-03-08
BR112015005817A2 (pt)	2017-07-04

Publication	Publication Date	Title
CL2015000711A1 (es)	2015-09-04	Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2021000008A1 (es)	2021-06-11	Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
IL272206B (en)	2022-02-01	Combination therapy for treating cancer
CL2015001985A1 (es)	2015-10-02	Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2015003280A1 (es)	2016-06-24	Derivados de benzimidazol como inhibidores de bromodominio
CL2016000807A1 (es)	2016-07-08	Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2014001829A1 (es)	2015-01-02	Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2016000153A1 (es)	2016-07-29	Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015001731A1 (es)	2015-08-28	Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
DK2818482T3 (da)	2019-07-15	Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da)	2019-07-29	Farmaceutisk sammensætning til behandling af cancer
CL2015002767A1 (es)	2016-12-30	Compuestos terapéuticos y composiciones
MX2016008131A (es)	2016-09-16	Compuestos heterociclos biciclicos y sus usos en terapia.
LT2984166T (lt)	2020-08-10	Kompozicijos, skirtos mpsi gydymui
CL2014002257A1 (es)	2014-12-05	Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
LT2916860T (lt)	2020-07-10	Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015001202A1 (es)	2015-07-03	Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2014000517A1 (es)	2014-08-22	Compuestos derivados de heterociclos nitrogenados condensados, moduladores de pi3k; composicion farmaceutica; y uso en el tratamiento de una enfermedad tal como asma, lupus, osteoartritis, esclerosis multiple, cancer, entre otras.
EA201590139A1 (ru)	2015-07-30	Шприц
UY34648A (es)	2013-09-02	Amidas como inhibidores de pim
EA201400178A1 (ru)	2014-11-28	Лечение рака молочной железы
CL2013001009A1 (es)	2013-08-30	Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer.